Sudarshan Sukhani of s2analytics.com is of the view that one can sell Lupin .
Sukhani told CNBC-TV18, "Lupin has been a big disappointment; it went up and after the first rally the correction never seems to end while most pharma stocks are willing to go up and then they give buy signals. Lupin is not doing anything."
He further added, "Yesterday it suggested that whatever small rally it has seen from Rs 400 to Rs 430-440 that may well be over. So Lupin in a choppy market, we get some stocks to sell because we are in an uptrend ratio will be skewed in favour of the buys but here Lupin is a sell because it could go below Rs 408, it's earlier low and the charts haven't changed, the correction persist."
The company's trailing 12-month (TTM) EPS was at Rs 16.24 per share. (Sep, 2011). The stock's price-to-earnings (P/E) ratio was 27.16. The latest book value of the company is Rs 70.59 per share. At current value, the price-to-book value of the company was 6.25. The dividend yield of the company was 0.68%.
